{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:34:53Z","timestamp":1793885693501,"version":"4.8.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtct.2026.06.022","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:49:37Z","timestamp":1781801377000},"page":"1495.e1-1495.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends and Disparities in Chimeric Antigen Receptor T-Cell Therapy Utilization, Inpatient Mortality, Length of Stay, and Costs in the United States (2017 to 2022)"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9551-3754","authenticated-orcid":false,"given":"Simo","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4028-383X","authenticated-orcid":false,"given":"Jiahao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6110-1773","authenticated-orcid":false,"given":"Tiantian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stepan M.","family":"Esagian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6974-5815","authenticated-orcid":false,"given":"Yating","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Lee-Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3640-7235","authenticated-orcid":false,"given":"Victor T.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Alejandro","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtct.2026.06.022_bib0001","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jtct.2026.06.022_bib0002","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.022_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.022_bib0004","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"14","key":"10.1016\/j.jtct.2026.06.022_bib0005","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jtct.2026.06.022_bib0006","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless-design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.022_bib0007","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.jtct.2026.06.022_bib0008","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a BCMA-directed CAR-T-cell therapy, in relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.022_bib0009","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.jtct.2026.06.022_bib0010","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.jtct.2026.06.022_bib0011","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jtct.2026.06.022_bib0012","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.022_bib0013","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1007\/s12325-024-02917-7","article-title":"Medicare utilization and cost trends for CAR T-cell therapies across settings of care in the treatment of diffuse large B-cell lymphoma","volume":"41","author":"Wu","year":"2024","journal-title":"Adv Ther"},{"issue":"16","key":"10.1016\/j.jtct.2026.06.022_bib0014","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1182\/bloodadvances.2024013239","article-title":"Outpatient administration of CAR T-cell therapies using a strategy of remote at-home monitoring and early CRS intervention","volume":"8","author":"Furqan","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.022_bib0015","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jtct.2023.03.012","article-title":"Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma","volume":"29","author":"Reyes","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.022_bib0016","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T-cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.022_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.28877","article-title":"Geographic and racial disparities in access to chimeric antigen receptor\u2013T cells and bispecific antibodies trials for multiple myeloma","volume":"5","author":"Alqazaqi","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"17","key":"10.1016\/j.jtct.2026.06.022_bib0018","first-page":"1607","article-title":"Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy","volume":"143","author":"Karmali","year":"2024","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jtct.2026.06.022_bib0019","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.022_bib0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11899-021-00635-3","article-title":"Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments","volume":"16","author":"Geethakumari","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.022_bib0021","doi-asserted-by":"crossref","first-page":"404.e1","DOI":"10.1016\/j.jtct.2022.03.021","article-title":"Health care resource utilization and total costs of care among patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy in the United States","volume":"28","author":"Keating","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.06.022_bib0022","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","volume":"43","author":"Scheffer Cliff","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"13 suppl","key":"10.1016\/j.jtct.2026.06.022_bib0023","first-page":"S253","article-title":"Improving outcomes and mitigating costs associated with CAR T-cell therapy","volume":"27","author":"Borgert","year":"2021","journal-title":"Am J Manag Care"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.022_bib0024","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41408-022-00657-x","article-title":"Acute seizures and status epilepticus in immune effector cell\u2013associated neurotoxicity syndrome (ICANS)","volume":"12","author":"Saw","year":"2022","journal-title":"Blood Cancer J"},{"issue":"36","key":"10.1016\/j.jtct.2026.06.022_bib0025","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.022_bib0026","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"issue":"suppl 16","key":"10.1016\/j.jtct.2026.06.022_bib0027","first-page":"CT212","article-title":"CT-212: national trends in the utilization of chimeric antigen receptor T-cell therapy","volume":"41","author":"Solipuram","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.022_bib0028","first-page":"262","article-title":"Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed\/refractory mantle cell lymphoma in the United States","volume":"31","author":"Kilgore","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.022_bib0029","doi-asserted-by":"crossref","first-page":"917.e1","DOI":"10.1016\/j.jtct.2024.06.021","article-title":"Current trends and outcomes in cellular therapy activity in the United States, including prospective patient-reported outcomes data collection in the CIBMTR registry","volume":"30","author":"Cusatis","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"23","key":"10.1016\/j.jtct.2026.06.022_bib0030","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1002\/cam4.4797","article-title":"Demographic differences among patients treated with chimeric antigen receptor T-cell therapy in the United States","volume":"11","author":"Emole","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtct.2026.06.022_bib0031","unstructured":"Agency for Healthcare Research and Quality (AHRQ). HCUP National (Nationwide) Inpatient Sample (NIS): overview and documentation. Accessed December 18, 2025. https:\/\/hcup-us.ahrq.gov\/nisoverview.jsp"},{"key":"10.1016\/j.jtct.2026.06.022_bib0032","unstructured":"Bureau of Labor Statistics. Consumer price index for all urban consumers: hospital services in U.S. City Average (CUUR0000SEMD01). US Department of Labor. Accessed November 18, 2025. https:\/\/data.bls.gov\/timeseries\/CUUR0000SEMD01"},{"key":"10.1016\/j.jtct.2026.06.022_bib0033","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"17","key":"10.1016\/j.jtct.2026.06.022_bib0034","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/bloodadvances.2024013540","article-title":"Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience","volume":"8","author":"Kalariya","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.022_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70192","article-title":"Sex differences in the clinical presentation of patients with newly diagnosed multiple myeloma","volume":"132","author":"Ong","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2026.06.022_bib0036","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40164-025-00684-x","article-title":"Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021","volume":"14","author":"Pan","year":"2025","journal-title":"Exp Hematol Oncol"},{"issue":"18","key":"10.1016\/j.jtct.2026.06.022_bib0037","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1182\/bloodadvances.2024015634","article-title":"Inequalities in CAR T-cell therapy access for US patients with relapsed\/refractory DLBCL: a SEER-Medicare data analysis","volume":"9","author":"Chung","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.06.022_bib0038","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1200\/EDBK_279151","article-title":"Expanding access to chimeric antigen receptor T-cell therapies: challenges and opportunities","volume":"40","author":"Kansagra","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.022_bib0039","doi-asserted-by":"crossref","first-page":"449.e1","DOI":"10.1016\/j.jtct.2023.04.019","article-title":"Patient characteristics and outcomes of outpatient tisagenlecleucel recipients for B-cell non-Hodgkin lymphoma","volume":"29","author":"Ahmed","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.06.022_bib0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41408-023-00961-0","article-title":"Addressing the disparities: the approach to the African American patient with multiple myeloma","volume":"13","author":"Bhutani","year":"2023","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.022_bib0041","first-page":"111","article-title":"Cancer statistics for African American and Black people, 2025","volume":"75","author":"Saka","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"18","key":"10.1016\/j.jtct.2026.06.022_bib0042","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.3390\/jcm12186098","article-title":"Outcomes of CAR-T cell therapy recipients admitted to the ICU: in search for a standard of care\u2014a brief overview and meta-analysis of proportions","volume":"12","author":"Constantinescu","year":"2023","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.022_bib0043","doi-asserted-by":"crossref","first-page":"108.e1","DOI":"10.1016\/j.jtct.2022.11.004","article-title":"Epidemiology and predictors of 30-day readmission in CAR-T cell therapy recipients","volume":"29","author":"Sharma","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.022_bib0044","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell\u2013associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.022_bib0045","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/bloodadvances.2023010401","article-title":"A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help","volume":"8","author":"Curran","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.022_bib0046","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1200\/OP-25-00062","article-title":"Outpatient administration of chimeric antigen receptor T-cell therapy using remote patient monitoring","volume":"21","author":"Majhail","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jtct.2026.06.022_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T-cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.022_bib0048","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/10428194.2022.2147395","article-title":"Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving CAR-T therapy: a retrospective cohort study using CMS 100% Medicare claims database","volume":"64","author":"Yang","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.022_bib0049","article-title":"Cost-effective strategies for CAR-T cell therapy manufacturing","volume":"33","author":"Abdo","year":"2025","journal-title":"Mol Ther Oncol"},{"issue":"181","key":"10.1016\/j.jtct.2026.06.022_bib0050","first-page":"58432","article-title":"Medicare program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and final policy changes and fiscal year 2021 rates (CMS-1735-F)","volume":"85","year":"2020","journal-title":"Fed Regist"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:18:10Z","timestamp":1793884690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726004896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666636726004896"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.022","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends and Disparities in Chimeric Antigen Receptor T-Cell Therapy Utilization, Inpatient Mortality, Length of Stay, and Costs in the United States (2017 to 2022)","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}